Eli Lilly and Company (NYSE: LLY) has announced a substantial $1 billion investment to expand its Limerick, Ireland, manufacturing site, which will increase the production of biologic active ingredients, including those for its newly approved treatment for early symptomatic Alzheimer’s disease. Simultaneously, the company unveiled a new $800 million facility expansion in Kinsale, Ireland, which […]
Eli Lilly and Company (NYSE: LLY) has announced promising results from the SURMOUNT-OSA phase 3 clinical trials of tirzepatide, a novel treatment aimed at moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Detailed results, published in The New England Journal of Medicine and presented at the American Diabetes Association’s 84th Scientific Sessions, reveal significant […]
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology firm, announced promising pre-clinical data for DA-1726, a novel oxyntomodulin (OXM) analog functioning as a dual agonist of glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The data was presented at the American Diabetes Association’s 84th Scientific Sessions in Orlando, Florida. The pre-clinical studies showcased DA-1726’s superiority […]
Sun Pharmaceutical Industries Limited unveiled data from its Phase 1 study of GL0034 (Utreglutide), targeting obesity in adults. The findings, presented at the 84th American Diabetes Association Scientific Sessions in Orlando, Florida, underscore significant weight loss and improved metabolic parameters among participants. The Phase 1, multiple ascending-dose study aimed to assess the safety, tolerability, pharmacokinetics, […]
Zealand Pharma A/S (Nasdaq: ZEAL), a pioneer in peptide-based drug development, has shared topline results from its DREAM trial, evaluating the efficacy of low doses of the GLP-1/GLP-2 receptor dual agonist, dapiglutide, in treating obesity. This clinical study marks a significant step forward in understanding the potential of dapiglutide to induce weight loss without lifestyle […]
Roche has announced positive outcomes from the Phase I clinical trial of CT-388, a novel dual GLP-1/GIP receptor agonist, which is being developed as a once-weekly subcutaneous injection for the treatment of obesity and type 2 diabetes. The trial results revealed significant weight loss and improved glycemic control in participants, positioning CT-388 as a potentially […]
The U.S. Food and Drug Administration (FDA) has recently granted an additional indication for Novo Nordisk’s Wegovy, a milestone in medical advancements aimed at combating cardiovascular diseases (CVD). This new approval positions Wegovy as the first treatment option specifically approved to reduce the risk of major cardiovascular events such as death, heart attack, or stroke […]
